-
Bone Therapeutics hires new chief business officer
Stefanos Theoharis, PhD, was appointed chief business officer of Bone Therapeutics on March 26. -
$2.5B in sales projected for Novartis' spinal muscular atrophy drug by 2025
Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, recently demonstrated significant therapeutic benefits for patients in various extended clinical trials, reports Pharmaceutical Technology. -
Novartis' $2.1M gene therapy drug gains Japanese approval, seeking approval in 30+ countries
The Japanese Ministry of Health, Labour and Welfare recently approved Zolgensma, Novartis' gene therapy drug for the treatment of spinal muscular atrophy, for infants under the age of 2, according to Medical Dialogues. -
Anika Therapeutics' vision of a biologics-led future
Regenerative medicine therapies hold much potential in the orthopedic space, despite the lack of comprehensive knowledge around the therapies. Here, Anika Therapeutics interim CEO Cheryl Blanchard, PhD, explains how the company plans to approach the biologics market. -
SpineOvations' DiscSeal study for low back pain completes enrollment — 3 insights
SpineOvations on Feb 24. finished enrollment for its DiscSeal clinical study in patients suffering from lumbar pain. -
The future of spinal biologics, regeneration and MIS treatment: Q&A with Dr. Roger Härtl
Roger Härtl, MD, has devoted much of his career to finding the best, least invasive treatment for back and neck pain. That mission has led him to research and innovate in the field of spinal biologics. -
Konica Minolta Healthcare expands regenerative medicine products for orthopedics
Konica Minolta Healthcare Americas partnered with RegenLab USA Feb. 19 to distribute its regenerative medicine portfolio for the orthopedic market in the U.S. and Canada. -
Biologic cocktail triggers release of stem cells, shows potential for spinal injuries
Early-stage research published in npg Regenerative Medicine demonstrated that two medications on the market can enhance the body's ability to heal by releasing stem cells from bone marrow, reports Science Blog. -
Stem cells in spine more hype than reality, says Dr. Neel Anand
Neel Anand, MD, serves as professor of orthopedic surgery and director of spine trauma at the Cedars-Sinai Spine Center in Los Angeles. -
US Department of Defense researchers to study spinal cord regeneration
Biopharmaceutical company MicroCures partnered Feb. 19 with the Henry M. Jackson Foundation for the Advancement of Military Medicine to study spinal cord regeneration after trauma. -
Stem cells may achieve 'breakthrough' in spine, but researchers must do due diligence, says Dr. Steven Cyr
Steven Cyr, MD, is a fellowship-trained spine surgeon who recently began providing stem cell treatments at SASpine in San Antonio. -
Dr. Frank Phillips: Key trends in spinal biologics and regeneration
Frank Phillips, MD, is the director of the section of minimally invasive spine surgery and director of the division of spine surgery at Chicago-based Rush University Medical Center. -
Coronavirus outbreak disrupts drug trial for spondyloarthritis, and other Chinese studies
Several clinical trials in China have been put on hold due to the coronavirus outbreak, including a treatment for a type of spondyloarthritis, according to Reuters. -
Regenexx celebrates 15 years, performed 90K+ procedures — 5 things to know
This year marks the 15th anniversary of orthobiologic physician group Regenexx. -
Onkos Surgical launches bone scaffold for orthopedic revision surgeries, tumors
Onkos Surgical on Feb. 6 launched GenVie Magnesium Bone Scaffold, a magnesium-based bone void filler for orthopedic conditions. -
'The most expensive drug in the world' — 10 details on Novartis' $2.1M drug for spinal muscular atrophy
Zolgensma, a gene therapy drug for spinal muscular atrophy, has been on the market since June 2019 and is widely reported to be the most expensive drug in the world. -
Dr. Steven Cyr offering spinal stem cell treatments at Texas clinic
Steven Cyr, MD, is now providing stem cell treatments at SASpine in San Antonio. -
Cleveland Clinic to test new drug for early detection of multiple sclerosis
Myeliviz, a new drug to help diagnose multiple sclerosis in its earlier stages was recently approved by the FDA for human clinical trials. -
$186M in Q4 sales delivered by Novartis gene therapy for spinal muscular atrophy
Zolgensma, Novartis' gene therapy drug for spinal muscular atrophy, totaled $186 million in fourth quarter sales, according to Stat. -
The spinal fusion market: 8 key points
Here are eight things to know about the spinal fusion market.
Page 13 of 34